Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug757 | COVID-19 Swab Wiki | 1.00 |
| drug2943 | Placebo Infusion Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002659 | Child Development Disorders, Pervasive NIH | 0.41 |
| D001321 | Autistic Disorder NIH | 0.30 |
| D000067877 | Autism Spectrum Disorder NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.30 |
| HP:0000729 | Autistic behavior HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).
Description: The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3). The primary endpoint is the change on this outcome measure from baseline to six months.
Measure: Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales Time: Baseline, 6 monthsDescription: Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score
Measure: Change in VABS-3 Socialization Standard Score Time: Baseline, 6 monthsDescription: Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score
Measure: Change in VABS-3 Communication Standard Score Time: Baseline, 6 monthsDescription: Clinical Global Impression- Severity Scale
Measure: Change in CGI-Severity score Time: Baseline, 6 monthsDescription: Clinical Global Impression- Impression
Measure: CGI-Intervention score Time: Baseline, 6 monthsDescription: Pediatric Quality of Life Scale
Measure: Change in the Pediatric Quality of Life Scale Time: Baseline, 6 monthsDescription: Assess for infusion reactions
Measure: Incidence and severity of infusion reactions Time: Baseline, 6 monthsDescription: Assess for infections directly related to the study product infusions
Measure: Incidence and severity of product-related infections Time: Baseline, 6 monthsDescription: Assess for anti-HLA antibodies
Measure: Evidence of formation of anti-HLA antibodies Time: Baseline, 6 months, 12 monthsDescription: Assess for signs and symptoms of graft versus host disease
Measure: Incidence and severity of graft versus host disease Time: 6 months, 12 monthsDescription: Assess for study related and unexpected adverse events
Measure: Incidence and severity of unexpected adverse events related to the study product Time: Baseline, 6 months, 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports